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Background: Few studies have evaluated survival, treatment, resource use, and costs among women with stage IV
ER + breast cancer (BC) who did not receive HER2 targeted therapy.
Methods: Using linked Surveillance, Epidemiology, and End Results (SEER) and Medicare data from 2006-2009,
women aged 66+ years with an incident diagnosis of stage IV ER + BC (index date) in 2007 and no HER2 targeted
therapy were identified. A comparison cohort without cancer was created from the SEER 5% Medicare sample
and matched 1:1 to the study cohort based on age, sex, and race. All patients had continuous enrollment for a
12-month baseline period prior to index and were followed until the end of the study window, disenrollment, or
death, whichever came first. Resource utilization and costs (by place of service, reported per patient per month,
PPPM) were compared across cohorts. Treatment patterns including receipt of surgery, radiation, chemotherapy,
aromatase inhibitors (AI), and non-AI hormonal therapy were evaluated for study cohort patients with at least
2 months of follow-up. Kaplan-Meier survival analysis was also conducted.
Results: 325 women with stage IV ER + BC without HER2 targeted therapy were identified and matched to 325
women without cancer. Mean age was 77 years for both cohorts, with average follow-up of 18 months for study
patients and 26 months for comparison patients. Compared to the comparison cohort, study patients had
significantly higher mortality (60.3% versus 31.1%, P < 0.001), shorter survival (survival at 36 months 28% vs. 62%)
and higher resource utilization across all settings except for oral prescription drugs. Total PPPM healthcare costs
were also significantly higher among study patients ($7,271 vs. $1,778, P < 0.001). Approximately 57% of study
patients with 2+ months of follow-up received chemotherapy and over 62% received an AI during follow-up.
Within 4 months of cancer diagnosis, surgery and radiation were received by 39% and 32% of study patients,
respectively.
Conclusions: We found significant excess clinical and economic burden among women with stage IV ER +
breast cancer who did not receive HER2 targeted therapy. Future studies with more precise and recent data are
warranted to confirm and extend these results.* Correspondence: jmenzin@bhei.com
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Breast cancer is the most common invasive cancer in
women and the second leading cause of death from cancer
among women in the United States (US) [1]. Approxi-
mately 1 in 8 women will be diagnosed with breast cancer
during her lifetime, and within the US in 2013 there will
be 232,340 newly diagnosed cases and 39,620 deaths asso-
ciated with the disease [2]. The majority of these deaths
result from recurrent or metastatic disease, which occurs
in 6% of newly diagnosed patients and approximately 30%
of those previously diagnosed with an earlier stage [3].
Treatment options for metastatic breast cancer include
systemic therapies (chemotherapy, hormone therapy), sur-
gery, and/or radiation [4]. Systemic therapies are the rec-
ommended primary treatment option for patients with
metastatic breast cancer, while surgery is generally consid-
ered, if appropriate, after initial systemic therapy [4]. Radi-
ation therapy may be considered as an alternative to
surgery or as palliative therapy [4].
Among other factors, tumor biology and clinical features
influence therapeutic strategy. The National Comprehen-
sive Cancer Network (NCCN) guidelines recommend all
patients newly diagnosed with breast cancer be tested for
hormone receptor status via expression of estrogen and/or
progesterone receptors (ER/PR) and human epidermal
growth factor receptor-2 (HER2) [4]. Endocrine therapy is
the preferred treatment for patients with stage III or IV
hormone-receptor-positive (HR +, which includes ER and/
or PR positive) breast cancer, but chemotherapy may also
be recommended for cases with rapidly progressive dis-
ease [4,5]. Recommended endocrine therapies for HR +
patients include tamoxifen, fulvestrant, megestrol, and
aromatase inhibitors, such as anastrazole, letrozole or exe-
mestane [4]. In addition, targeted therapies such as evero-
limus plus exemestate (Afinitor, Novartis Pharmaceuticals,
Basel) have recently been approved or are in further clin-
ical development for HR + advanced breast cancer [6].
Few population-based studies of survival among women
with advanced HR + breast cancer exist. A recently pub-
lished study of SEER registry data by Johnson and col-
leagues estimated 5-year survival of distant breast cancer to
be 31% [7]; however, Johnson did not report survival by
hormone receptor status. Jung and colleagues reported me-
dian survival of approximately 45 months among women
with either ER or PR positive metastatic BC in a single large
urban practice [8]. Furthermore, there are limited published
studies on resource use and costs in this population. A re-
cent systematic review of the literature on the burden of
ER + advanced breast cancer found only one study on the
economic burden of ER + patients which was focused on
the impact of recurrence [9]. Given that approximately 80%
of ER + patients would not be indicated to receive HER2
targeted therapy [10], we have focused our study on those
ER + patients who did not receive a HER2 targeted therapy.We conducted a retrospective database analysis of sur-
vival, treatment patterns, healthcare resource use, and costs
using the Surveillance and Epidemiology End Results data-
base linked to Medicare claims (SEER-Medicare). We iden-
tified women diagnosed with stage IV ER + breast cancer
who received immunohistochemistry or fluorescence in situ
hybridization (FISH) testing and did not receive a HER2
targeted agent (trastuzumab or lapatinib) and compared
them to a matched comparison cohort of women without
cancer. This primary population was chosen as women
with ER + and HER2 - breast cancer represent the largest
patient population among all BC patients.
Methods
Data source
The linked SEER-Medicare database is a collaborative ef-
fort of the National Cancer Institute (NCI), the SEER
registries, and the Centers for Medicare and Medicaid
Services (CMS). SEER is an epidemiologic surveillance
system consisting of population-based tumor registries de-
signed to track cancer incidence and survival in the US.
The registries routinely collect information on newly diag-
nosed cancer patients in geographically defined areas that
represent approximately 25% of the US population. The
registries ascertain all newly diagnosed cancer cases from
multiple reporting sources such as hospitals, outpatient
clinics, laboratories, private clinics, nursing homes, hos-
pice, autopsy reports, and death certificates. The linked
SEER-Medicare data files are not publicly available; inves-
tigators and researchers must obtain approval from the
NCI for specific research objectives in order to obtain the
data. Approval is granted at the discretion of the NCI to
ensure confidentiality and protection of the patients and
providers in SEER registries. Such approval and subse-
quent access to the data for this study were granted by the
NCI following submission of a formal data request outlin-
ing the research objectives. The National Institutes of
Health's Office of Human Subjects Research has deter-
mined that analyses using SEER-Medicare data are exempt
from requiring further IRB review and approval.
The database used in this study included breast can-
cer cases diagnosed in 2007 with Medicare claims from
2006 through 2009. In addition, data for a 5% Medicare
sample were used to create a comparison cohort. The
database includes a SEER file of patients diagnosed with
cancer within the geographic areas covered by SEER
registries (Patient Entitlement and Diagnosis Summary
[PEDSF] file), as well as Medicare claims covering the
period up to two years after the last year of available
SEER data. The Medicare administrative claims files in-
clude individual claims for inpatient and skilled nursing
facility (SNF) hospitalizations (Medicare Provider Analysis
and Review [MEDPAR] file), outpatient hospital visits and
miscellaneous ambulatory services (Outpatient file), home
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(Hospice file), carrier claims (NCH file, formerly the Phys-
ician/Supplier file), durable medical equipment (DME file),
and Part D prescription drug claims (PDE file). Part D pre-
scription data were only available for 2007-2009.
Patient selection and follow-up
Two cohorts were selected for this study: a cohort of
stage IV ER + breast cancer patients who received anFigure 1 Patient selection.immunohistochemistry or FISH test and did not re-
ceive a HER2 targeted agent (study cohort), and a
matched comparison cohort of women who did not
have cancer at the start of follow-up (comparison co-
hort). All patients in both cohorts were required to
meet the following criteria:
 66 years or older at index date (to allow 1 year
baseline period);
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benefits at all points during the study period (including
a 12-month baseline period prior to index date);
 Not enrolled in an HMO during any study month;
 Medicare entitlement not based on end stage renal
disease (ESRD) or disability; and
 No claims after date of death
Female patients with an incident diagnosis of stage IV
breast cancer (SEER site recode 46, AJCC stages 'IV',
'IVNOS', 'IVA', 'IVB', or 'IVC') between 1/1/2007 and
12/31/2007 were identified for possible inclusion in the
study cohort, with the date of cancer diagnosis serving
as the index date. This cohort was then limited to
women who met the following additional criteria:
 Breast cancer was identified as the patient’s primary
cancer using SEER variables indicating the order of
incident cancer diagnoses for a given patient
(i.e., first cancer site was the primary cancer).
 Breast cancer was ER +, identified using the SEER
breast cancer site-specific factor variable for an
estrogen receptor assay. Patients were classified as
ER + if the ER assay was positive/elevated
 Received an immunohistochemistry or
fluorescence in situ hybridization (FISH) test
during or following the month of breast cancer
diagnosis. Tests were identified if any of the
following CPT codes were noted on a claim: 88342,
88360, 88361, 88365, 88271, 88274, 88291, 88367,
88368, 83950
 Did not receive a HER2 targeted agent (i.e.,
trastuzumab (Herceptin®, Roche), lapatinib (Tykerb,
GSK) any time after the test mentioned above
 No (prior) history of any other (non-breast) cancer
diagnosis before breast cancer diagnosis
 Diagnosis of breast cancer was not at time of death
or autopsy
To create the comparison cohort, one randomly se-
lected patient of identical age, sex and race was matched
to each study cohort patient and assigned the same
index date (to follow them over the same time period).
Comparison patients were selected from the Medicare
enrollment files using a 5% sample of Medicare benefi-
ciaries residing in SEER areas who had not been re-
ported to any of the SEER registries as having any
cancer prior to their index date. These patients were
not required to have used services in order to be se-
lected for inclusion, and were allowed to develop can-
cers other than breast cancer after their index date. All
patients were followed until the end of the study win-
dow (12/31/2009), disenrollment, or death, whichever
came first.Study measures
Baseline demographic and clinical characteristics were
assessed over a 12-month period preceding the index date.
These included age, race, region, urban/rural area, Charlson
comorbidities and score [11,12], presence of other comor-
bidities commonly present among breast cancer popula-
tions such as osteoporosis and fractures (identified based
on the presence of any of the following ICD-9 diagnosis
codes: 733.0x, 805.xx, 807.0x-807.4x, 808.xx, 809.xx, 813.
xx-814.xx, 820.xx-821.xx, 733.1x) and depression or anx-
iety (identified based on the presence of any of the follow-
ing ICD-9 diagnosis codes: 296.2x, 296.3x, 300.4, 309.0x,
309.1x, 311.xx), and progesterone receptor (PR) status
(identified using the SEER breast cancer site-specific factor
variable for a PR assay). Mortality rates and time from
index date to death were also evaluated, with Kaplan-
Meier survival analysis conducted for overall survival.
Among patients in the study cohort, we evaluated the
percent undergoing surgery related to the primary cancer
site or radiation within 4 months of initial breast cancer
diagnosis using SEER-created summary fields. We also
evaluated the percent of patients prescribed chemother-
apy, aromatase inhibitors (AI), and non-aromatase inhibi-
tor hormonal therapy (non-AI). AIs included anastrazole,
letrozole, and exemestane. Non-AIs included fulvestrant,
tamoxifen, toremifene, and megestrol. Receipt of each
treatment (i.e., chemotherapy, AIs, non-AIs) was identi-
fied based on the presence of the corresponding NDC
codes or HCPCS codes. These treatment patterns were
only evaluated among patients with at least 2 months of
follow-up to allow for treatment observation. Patients
who received more than one type of treatment during
the follow-up period were considered to have received
combination regimens.
Resource utilization during the follow-up period was
assessed using the following measures: percent with at least
one hospitalization, number of hospital admissions (defined
as number of unique records in the inpatient claims file as
each record represented a unique hospitalization), total
hospital days per patient (defined as the sum of hospital
days for all hospitalizations for a given patient), percent
with office/clinic visits and number of visits (defined as
number of unique days with such visits), percent with phys-
ician/provider claims and number of visits (defined as num-
ber of unique days with such claims), percent receiving
prescriptions for oral drugs, percent with home health care
use, percent with skilled nursing facility (SNF) use, percent
with hospice use, and percent with durable medical equip-
ment (DME) use. The setting of resource use was based on
the source file of the encounter, as SEER-Medicare provides
separate claims files for inpatient, outpatient office/clinic,
physician/provider, Part D pharmacy, home health care,
SNF, hospice, and DME encounters. Total healthcare costs
during the follow-up period were estimated by summing all
Table 1 Sociodemographic and clinical characteristics and
duration of follow-up for Medicare-eligible stage IV ER +
breast cancer patients who did not receive HER2 targeted
















Urban (%) 99.1% 96.6% 0.055





Duration of follow-up (months)
Mean ± SD 18.12 ± 11.91 25.82 ± 8.94 < 0.001
Median 20.00 28.00
Charlson score**









Congestive heart failure 14.2% 12.0% 0.485








Rheumatologic disease 4.3% 5.2% 0.713
Myocardial infarction 3.7% 4.3% 0.842
Dementia 2.2% 8.3% < 0.001
Peptic ulcer disease 0.9% 2.2% 0.340




Table 1 Sociodemographic and clinical characteristics and
duration of follow-up for Medicare-eligible stage IV ER +
breast cancer patients who did not receive HER2 targeted
agents and matched comparison patients (Continued)
AIDS 0.0% 0.0% < 0.001
Mild liver disease 0.0% 0.6% 0.499
Other comorbidities (%)
Depression/anxiety 9.2% 17.8% 0.002





**Charlson score excludes any primary malignancy and metastatic solid tumor.
***Proportions were compared using the Fisher's exact test while continuous
measures were compared using the nonparametric Wilcoxon test.
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ibles across all settings. Total costs for each resource use
setting were also evaluated.
Data analysis
Descriptive analyses of all study measures were performed.
Binary variables were summarized using percentages and
continuous variables were summarized using means,
standard deviations (SD), and medians. Analyses of re-
source use and costs were conducted on a per-patient-
per-month (PPPM) basis to allow for variable follow-up
lengths. Statistical testing between the two cohorts was
conducted for mortality rates, healthcare costs, and overall
survival. Continuous variables were tested using the non-
parametric Wilcoxon test, proportions were tested using
the Fisher’s exact test, and survival was tested using the
Log-Rank test. All cost measures were adjusted to 2011
US dollars using the medical care component of the con-
sumer price index. All analyses were conducted using SAS
software (Version 9.3, SAS Institute, Cary, NC).
Results
Patient selection and baseline demographic
characteristics
A total of 325 women meeting all eligibility criteria were
identified as having an incident diagnosis of stage IV ER +
breast cancer and no HER2 targeted therapies following
diagnosis. Figure 1 presents the full patient selection re-
sults. Among the 325 comparison patients, 7 patients
(2.2%) developed a non-breast cancer during the follow-
up period, and the remaining 318 patients did not have
any cancer diagnoses during follow-up.
The mean age for both cohorts was 77 years, with 37% of
patients being 80 years or older. The majority of patients
(85.5%) were white, followed by black (10.2%) and Asian
(2.2%). Over 99% of study patients and approximately 97%
Table 2 Treatment patterns among Medicare-eligible
Stage IV ER + breast cancer patients who did not receive
HER2 targeted agents
Characteristic Study cohort
With > 2 months of follow-up to allow for treatment
N 285
% 87.7%
Receiving surgery within 4 months of diagnosis
N 110
% 38.60%






Type of treatment received (at any time post-index)
Chemotherapy alone 15.1%
Aromatase Inhibitors (AI) therapy
Anastrazole monotherapy 11.8%
Letrozole monotherapy 9.4%
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pared to comparison patients, there were more study pa-
tients in the Northeast (30.8% vs. 19.1%) and fewer from
the West (34.8% vs. 42.5%). Average follow-up was shorter
for study patients (18.1 vs. 25.8 months) compared to com-
parison patients (see Table 1), which included the period
from index date to the end of the study window (12/31/
2009), disenrollment, or death, whichever came first.
Clinical characteristics
Baseline Charlson scores (excluding any primary malig-
nancy and metastatic solid tumor) were relatively similar
between the two cohorts (1.1 ± 1.6 [mean ± SD] among
study patients and 1.3 ± 1.7 among comparison patients).
Diabetes, chronic pulmonary disease, cerebrovascular dis-
ease and congestive heart failure were common comorbid-
ities in both cohorts. Over 9% of the study cohort and
almost 18% of the comparison cohort had depression/anx-
iety during the baseline period (P = 0.002). Similarly,
osteoporosis or osteoporosis-related fracture prevalence
was significantly lower in the baseline period for study pa-
tients (14.5% vs. 25.8%, P < 0.001). Over three-quarters of
study patients were PR + (78%) (see Table 1).Exmenestane monotherapy 1.4%






Multiple non-AI therapies 0.5%
Chemotherapy combined with AI therapy 11.8%
Chemotherapy combined with non-AI therapy 15.1%
AI therapy combined with non-AI therapy 10.4%
Chemotherapy combined with AI and
non-AI therapy
15.1%
Duration of any treatment (months)
Mean ± SD 12.9 ± 9.1
Median 11.0
Duration of AI treatment (months), among
those with any AI use
Mean ± SD 11.0 ± 8.1
Median 9.5Treatment patterns
Among the 285 (87.7%) study patients with at least
2 months of follow-up (to allow for treatment analysis),
38.6% received surgery and 31.9% received radiation within
4 months of their initial breast cancer diagnosis. Approxi-
mately three-quarters (74.4%) of these patients were pre-
scribed some type of cancer medication (see Table 2). More
than half of patients (57.1%) were prescribed chemotherapy
at some point after their diagnosis (15.1% chemotherapy
only, 15.1% chemotherapy with a non-AI, 15.1% chemo-
therapy with both an AI and non-AI, and 11.8% chemo-
therapy with an AI). Receipt of both an AI and a non-AI
during follow-up was also common (10.4%), as was anastra-
zole monotherapy (11.8%) and letrozole monotherapy
(9.4%). Over 62% of patients were prescribed an AI at some
point during follow-up. Among those who received any
medication, the mean (±SD) duration of treatment was
12.9 months (±9.1). The mean durations for AI, non-AI
and chemotherapy among those who received them were
11.0 (±8.1), 5.6 (±5.4), and 8.5 (±7.2) months, respectively.Duration of non-AI treatment (months),
among those with any non-AI use
Mean ± SD 5.6 ± 5.4
Median 4.0
Duration of chemo treatment (months),
among those with any chemo use
Mean ± SD 8.5 ± 7.2
Median 6.0Survival
Almost twice as many study patients died during the evalu-
ation period compared to comparison patients (60.3% vs.
31.1%, P < 0.001). The median time to death among those
who died was 8 months for study patients and 19 months
for comparison patients (P < 0.001). In Kaplan-Meier sur-
vival analysis, median survival for study patients was
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comparison patients (see Figure 2).
Resource use and costs
Study patients had significantly higher resource utilization
levels across most resource settings, including inpatient
utilization (83.1% with hospitalization vs. 47.4%, P < 0.001),
use of physician/provider services (100.0% vs. 98.2%, P =
0.031), SNF care (33.2% vs. 17.8%, P < 0.001), home health
care (47.4% vs. 21.2%, P < 0.001), hospice use (34.2% vs.
7.7%, P < 0.001), and use of DME (60.0% vs. 45.5%, P <
0.001; see Table 3). While the percent of patients with out-
patient office/clinic visits was not different (90.2% vs.
84.9%, P = 0.057) the mean PPPM number of visits was sig-
nificantly higher among study patients (0.9 vs. 0.4, P <
0.001). The percent of patients receiving any prescription
drugs (covered by Part D) was not different between the
two cohorts (58.5% vs. 60.0%, P = 0.750).
Total PPPM healthcare costs were over four times
higher among study patients $7,271 vs. $1,778, P <
0.001). The major cost drivers were inpatient care
($2,957 vs. $666, P < 0.001) and physician/provider ser-
vices ($2,104 vs. $393, P < 0.001). Similar to resource
utilization, study patients had significantly higher costs
across all resource settings except pharmacy costs for oral
drugs (see Figure 3).Figure 2 Kaplan-Meier survival analysis for Medicare-eligible stage IV
agents and matched comparison patients. Note: Median survival for the
comparison cohort during the study period.Discussion
Summary
This study compared a cohort of women diagnosed with
incident stage IV ER + breast cancer who received im-
munohistochemistry or FISH test and did not receive a
HER2 targeted agent to an age, sex and race matched
cohort of patients without cancer. The mortality rate in
the study cohort was almost double that in the compari-
son cohort (60% versus 31%). Not surprisingly, study pa-
tients also had significantly higher rates of resource
utilization and healthcare costs on a PPPM basis. While
all study patients were initially diagnosed with metastatic
breast cancer, almost one-third of these women under-
went surgery or radiation within four months of diagno-
sis. Additionally, approximately 57% of study patients
received some type of chemotherapy and over 62% re-
ceived an AI during the follow-up period.
Comparison to literature
There are limited published studies evaluating burden of
disease in women with stage IV ER + breast cancer. Papers
that do report survival by ER status seem to report a wide
range of estimates. A recent systematic literature review by
Boswell and colleagues [9] identified only one study during
2000-2011 that evaluated burden of disease based on ER
status [13]. This study by Stokes et al. found that elderlyER + breast cancer patients who did not receive HER2 targeted
study cohort was 23 months and it was not reached for the
Table 3 Resource utilization for Medicare-eligible stage IV ER + breast cancer patients who did not receive HER2
targeted agents and matched comparison patients
Characteristic Study cohort Comparison cohort P-value*
N 325 325
Percent hospitalized 83.1% 47.4% < 0.001
Hospital admissions (PPPM)
Mean ± SD 0.2 ± 0.3 0.1 ± 0.1 < 0.001
Median 0.1 0.0
Hospital days (PPPM)




Percent with outpatient office/clinic visits 90.2% 84.9% 0.057
Outpatient office/clinic visits (PPPM)
Mean ± SD 0.9 ± 0.9 0.4 ± 0.6 < 0.001
Median 0.8 0.2
Physician/provider claims
Percent with physician/provider claims 100.0% 98.2% 0.031
Physician/provider visits (PPPM)
Mean ± SD 4.5 ± 3.2 1.8 ± 1.6 < 0.001
Median 3.5 1.4
Percent receiving prescription drugs** 58.5% 60.0% 0.750
Percent receiving SNF care 33.2% 17.8% < 0.001
Percent receiving home health care 47.4% 21.2% < 0.001
Percent receiving hospice care 34.2% 7.7% < 0.001
Percent with DME claims 60.0% 45.5% < 0.001
*Proportions were compared using the Fisher's exact test while continuous measures were compared using the nonparametric Wilcoxon test.
**Covered by Part D.
DME: Durable Medical Equipment; PPPM: per-patient-per-month; SNF: Skilled Nursing Facility.
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using a claims-based algorithm, appeared to have a distant
recurrence survived a median of 9 months following recur-
rence [13]. This is much lower than our median survival es-
timate of 23 months, likely due to the fact that the
population in the Stokes et al. paper was diagnosed almost
20 years ago and there were fewer therapies available (e.g.,
almost no hormonal therapy available). In addition, Stokes
et al. consisted of patients diagnosed at earlier stages than
our population with incident ER +metastatic cancer. Jung
and colleagues examined survival among metastatic breast
cancer patients of all ages who were diagnosed between
1999 and 2008, and found that those with ER +/PR + status
had a median survival of 45 months [8]. This was much
longer than we observed (23 months among all ER + pa-
tients and 26 months among ER +/PR +), as would be ex-
pected given the younger patient population studied
(median age of 55 vs. 77 years in our study). Rao et al. ex-
amined Medicare-eligible women with metastatic breast
cancer as well and found a similar mortality rate as in ourstudy (68% in the Rao et al. and 60% in our study); how-
ever, median survival was shorter (15 months vs. 23 months
in our study) [14]. This difference may be expected as their
study included all metastatic breast cancer patients and
ours was restricted to those that were ER + and not receiv-
ing a HER2 targeted agent. It has been shown that patients
with ER + breast cancer have better survival rates than
other sub-types of breast cancer [10].
We found a significant excess cost burden among stage
IV ER + breast cancer patients not treated with HER2
targeted therapy. Rao and colleagues also compared Medi-
care eligible women with metastatic breast cancer to non-
cancer controls, finding significantly higher costs among
those with breast cancer [14]. When adjusted to 2011
USD and standardized to a PPPM rate, their estimate of
total healthcare costs for the cancer cohort was $3,511,
which is about half of our PPPM estimate of $7,271 in
health care costs for study patients. As described above, a
similar proportion of the population died during the
evaluation period, but the median time of survival was
Figure 3 Per-patient-per-month health care costs for Medicare-eligible stage IV ER + breast cancer patients who did not receive HER2
targeted agents and matched comparison patients. Note: All differences between the two cohorts were significant at P <0.001, with the
exception of Pharmacy which was P = 0.082. Statistical significance was tested using the nonparametric Wilcoxon test.
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PPPM observed in the follow-up period among our
study patients (0.10 vs.0 .24 hospitalizations in our
study). This disparity may also be related to difference
in the population evaluated (all metastatic breast cancer
in Rao vs. stage IV ER + and not receiving trastuzumab
or lapatinib in our study).
Despite the fact that surgery of the primary site is not
regularly recommended in patients with primary meta-
static cancer [4,15], we observed a relatively high rate of
surgery in the first four months after diagnosis. This is
not unexpected given several recent studies that have
found that resection of the primary tumor in metastatic
patients may improve survival [15-18].
Limitations
This study is subject to the limitations of retrospective
claims-based analyses, such as coding errors and incom-
plete data [19]. The SEER-Medicare database is not repre-
sentative of all patients in the United States and does not
capture those with other forms of health insurance (e.g.,
managed care, private). Additionally, only women over the
age of 65 were evaluated. Therefore, this population may
not be representative of the entire stage IV ER + breast can-
cer population. Medicare claims were only availablethrough 2009 and may not capture all relevant healthcare
costs. In addition, only treatments available up to 2009
were captured in the analysis, so recently approved ther-
apies, such as everolimus, were not part of this analysis.
Furthermore, continuous enrollment in Part D was not a
requirement for study inclusion and therefore we may not
have complete pharmacy claims for all patients, limiting
the treatment data available. The sequence of treatment
(e.g., first line/second line treatment) was not evaluated in
this study as it was not a primary research objective, how-
ever, future studies evaluating lines of therapy would be
beneficial in this population.
An additional limitation of this study is it is not clear
why patients in the study cohort did not receive HER2 tar-
geted therapy. This may be related to the patient’s HER2
status, or the presence of a contraindication for HER2 tar-
geted therapy. In the years of data available, HER2 status
was not collected by the SEER registries, and therefore we
were unable to analyze the reason patients did not receive
HER2 targeted therapy. Fortunately, SEER began collect-
ing data on HER2 status in 2010.
Because the HER2 targeted agent lapatinib is an oral
drug and Part D pharmacy claims were only available from
2007 forward, we were unable to include cases from previ-
ous years, limiting our sample size. This study only
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breast cancer and did not include women who may have
been diagnosed at an earlier stage and then progressed.
Conclusions
The ER +metastatic breast cancer population is an under-
studied sub-type of breast cancer. This retrospective ana-
lysis found that there is a significant excess clinical and
economic burden among women with metastatic ER +
breast cancer who were not prescribed a HER2 targeted
agent when compared to age, sex, and race matched pa-
tients without cancer. Future studies with more precise
and recent clinical data paired with cost data are needed
in this population to confirm and extend these results.
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